X

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STI 6643 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Sorrento Therapeutics

Most Recent Events

12 Jan 2023 Planned End Date changed from 1 Dec 2024 to 1 Mar 2025.
12 Jan 2023 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2024.
22 Sep 2022 Planned number of patients changed from 24 to 100.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com